Search results
Results from the WOW.Com Content Network
The parent compound is uncommon, [2] but derivatives of 1,4-dihydropyridine are important commercially and biologically. The pervasive cofactors NADH and NADPH are derivatives of 1,4-dihydropyridine. 1,4-Dihydropyridine-based drugs are L-type calcium channel blockers, used in the treatment of hypertension. 1,2-Dihydropyridines are also known ...
Dihydropyridine (DHP) calcium channel blockers are derived from the molecule dihydropyridine and often used to reduce systemic vascular resistance and arterial pressure. Sometimes when they are used to treat angina , the vasodilation and hypotension can lead to reflex tachycardia , which can be detrimental for patients with ischemic symptoms ...
Compared with certain other L-type calcium channel blockers (for example those of the phenylalkylamine class such as verapamil) that have significant action at the heart, the dihydropyridine calcium channel blockers lower blood pressure mainly by relaxing the smooth muscle of the blood vessel walls. [3]
Isradipine (tradenames DynaCirc, Prescal) is a calcium channel blocker of the dihydropyridine class. It is usually prescribed for the treatment of high blood pressure in order to reduce the risk of stroke and heart attack. It was patented in 1978 and approved for medical use in 1989. [1]
Clevidipine is a dihydropyridine L-type calcium channel blocker, highly selective for vascular, as opposed to myocardial, smooth muscle and, therefore, has little or no effect on myocardial contractility or cardiac conduction. It reduces mean arterial blood pressure by decreasing systemic vascular resistance.
Hantzsch ester refers to an organic compound with the formula HN(MeC=C(CO 2 Et)) 2 CH 2 where Me = methyl (CH 3) and Et = ethyl (C 2 H 5). It is a light yellow solid. The compound is an example of a 1,4-dihydropyridine. It is named after Arthur Rudolf Hantzsch who described its synthesis in 1881.
It is a calcium channel blocker of the dihydropyridine type. [2] Nifedipine is taken by mouth and comes in fast- and slow-release formulations. [2] Common side effects include lightheadedness, headache, feeling tired, leg swelling, cough, and shortness of breath. [2] Serious side effects may include low blood pressure and heart failure. [2]
[1] [2] The initial reaction product is a dihydropyridine which can be oxidized in a subsequent step to a pyridine. [3] The driving force for this second reaction step is aromatization. This reaction was reported in 1881 by Arthur Rudolf Hantzsch. A 1,4-dihydropyridine dicarboxylate is also called a 1,4-DHP compound or a Hantzsch ester.